ArticleFrontiers in immunology2026
Clinical impact of first-line chemotherapy combined with immune checkpoint inhibitors for limited-stage small cell lung cancer patients: a real-world propensity score matching study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Findings from the ADRIATIC clinical trial revealed that adjuvant treatment with durvalumab following chemoradiotherapy (CRT) in limited-stage small cell lung cancer (LS-SCLC) significantly improved both overall survival (OS) and progression-free survival (PFS). However, the clinical impact remains uncertain in real-world clinical practice. Materials and methods: We gathered data of LS-SCLC patients at the First Affiliated Hospital of Zhengzhou University and conducted propensity score-matched analysis (PSM), Kaplan-Meier (K-M) method and Cox proportional hazards regression. Results: Prior to PSM, survival results demonstrated the mOS of the chemotherapy group was 20.34 months (95% confidence interval ( Conclusion: These results offer reliable references for clinicians when formulating treatment strategies for LS-SCLC patients and also provide support for future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.